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Abstract  
This article reviews will focus on the concept and formation of micro particles (MPs) in circulation and their role in 
transfusion medicine and immune system. MPs are cell membrane derived vesicles which express markers of their 
parent cells and are found in circulation at low levels. Exact functions of MPs are unclear. In here, Physiological 
almost all types of circulating MPs including platelets MPs (PMPs), leukocytes MPs (LMPs), red blood cells MPs 
(RMPs) and endothelial cells MPs (EMPs) have been discussed. Furthermore, MPs present in plasma and blood 
products and their levels increase during storage. Thus, it can be stated that MPs are likely to cause transfusion 
reactions, particularly thrombotic complications and Transfusion-Related Acute Lung Injury (TRALI). Also, it is 
shown that the MPs may affect the immune system. However, to prove these, more and extensive studies both in 
vivo and in vitro need to be done. 
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Microparticles (MPs), microvesicles or 
ectosomes are membrane derived vesicles that are 
released in blood flow. Most of cells including 
platelets, endothelial cells, tumor cells, erythrocytes 
and white blood cells (neutrophils, monocytes- 
macrophages and lymphocytes) produce MPs (1-3). 
They are found in physiological and pathological 
fluids (4-10) and are also produced in stored blood 
products (1-3). Mammalian cells secrete two 
extracellular vesicles; exosomes and MPs. Both are 
derived from the membrane, but their formation from 
cells membrane is different (11). Typically, MPs 
range in size from 0.1 µm to 1 µm. Exosomes, another 
form of secretory vesicles are smaller vesicles that 
range in size from 0.03 µm to 0.1 µm. Indeed, MPs are 
larger than exosomes and are derived directly from the 
plasma membrane. On the other hand, apoptotic 
bodies range in size from 1 to 5 micrometers (12-14). 
MPs and exosomes can be separated by differential 
centrifugation, ultrafiltration, ultracentrifugation, or 
immune-precipitation (13, 15). According to 
proteomic data, MPs-bound IgM probably provide a 
mechanism for clearance of MPs (16). Information 
relating to MPs, exosomes and apoptotic bodies are 
described in Table 1 (12-14, 17-21). This review will 
focus on the concept of MPs. Special emphasis will be 
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put on the effects of them in transfusion medicine 
and adaptive immunity system. 
The concept of MP and its 
formation 
 Existence of MPs was first noticed by Wolf in 
1967 (22). They are commonly described as a 
heterogeneous population of phospholipid vesicles, 
which are released by budding of the parental cells 
plasma membrane which is called ectocytosis (17, 
18). Although the MPs have been considered as cell 
dust with no any biological function, but it is known 
that they are involved in the biological activities such 
as hemostasis, thrombosis and inflammation (23). 
MPs release is a highly regulated process (16) 
that prompted by stimuli such as shear stress, 
complement activation, injury or apoptosis. 
However, the rate of release of them in the blood of 
healthy individuals is usually low (13). The 
formation of MPs is secondary to disruption of the 
normal phospholipid asymmetry of plasma 
membrane. Under physiologic conditions, the 
aminophosphiolipids including phosphatidylserine 
(PS) and phosphatidylethanolamine (PE) are 
arranged on the inner leaflet of membrane, but the 
cholinophospholipids including phosphatidylcholine 
(PC) and sphingomyelin (SM) are arranged on the 
outer leaflet of membrane. The transbilayer lipid 
distribution is under the control of three 
phospholipidic pumps: an inward-directed pump, 
or flippase; an outward-directed pump, or floppase; 
and a lipid scramblase, responsible for non-specific 
redistribution of lipids across the membrane. In 
resting cells, flippase maintains the asymmetry of the 
phospholipid bilayer but floppase and scramblase are 
inactive, and the cytoplasm calcium concentration is 
low. After cell stimulation, including apoptosis, a 
subsequent cytosolic Ca2+ increase promotes the loss 
of phospholipid asymmetry of the plasma membrane, 
subsequent phosphatidylserine exposure, and a 
transient phospholipidic imbalance between the 
external leaflet at the expense of the inner leaflet, 
leading to budding of the plasma membrane and MPs 
release. Indeed, loss of membrane stability allows the 
possibility of formation and release MPs. Also, in 
platelets, a significant change in membrane 
associated proteins leading to the generation of MPs. 
This change in red blood cells is less (23-25). The 
physiological role of MPs is not identified (23). 
However, it should be noted that Phosphatidylserine 
(PS) on the surface of MPs and apoptotic cells is a 
recognition signal for removal these vesicles and cells 
from the circulation by activated macrophages (26).  
Effects MPs in transfusion 
medicine  
MPs in blood components 
 MPs express surface markers from their 
parental cells. Thus, they can be classified according 
to the parental cell. There are four major subgroups of 
circulating MPs including platelets MPs (PMPs), 
leukocytes MPs (LMPs), red blood cells MPs (RMPs) 
and endothelial cells MPs (EMPs) (12, 14). It should 
be noted that probably all eukaryotic cells can produce 
MPs after stimulation or apoptosis because there is no 
accepted way to show the existence of MPs in tissues 
(27). 
Microparticles are present in all of blood 
products and accumulated during storage (28-30). The 
mechanism of MPs release is not exactly understood; 
but several mechanisms are probably involved, 
including shear stress, calcium influx, oxidative stress 
and complement attack. Also, in here, there are 
different types of MPs in blood products such as 
platelet MPs (PMPs), leukocyte MPs (LMPs) or red 
blood cells MPs (RPMs) (31, 32).   
 Accumulating of MPs is considered as a 
storage lesion (33). The level of vesiculation in RBCs 
products may change with the length of storage, 
storage solution, pre-storage leukoreduction and donor 
to donor. Additive solutions minimize production of 
RMPs through decreased oxidative stress. 
Furthermore, reduced RMPs has been seen after pre-
storage leukoreduction of whole blood or packed 
RBCs products (34, 35). In stored RBC products, 
RMPs are the predominant types. Nevertheless, 
noteworthy amount of PMPs and LMPs are produced 
during blood storage. After 10 days, Steep increase in 
the production of RMPs becomes more (28).  
 Platelet products are different from other blood 
products because they are stored between 20-24 °C 
with continuous gentle agitation and their life span is 
short, about 5 to 7 days (36). This limitation is as a 
The effect of cell derived microparticles in transfusion medicine and adaptive immunity system                         Esmaeili et al. 
Vol 2, No 1,  Winter 2016 
31 
result of the following two: the first case is bacterial 
contamination and the second is a platelet storage 
lesion (37). It is believed that more than one 
mechanism involved in the formation of MPs that 
most important of them include shear stress and 
biological factors such as cytoskeletal reorganization, 
plasma membrane blebbing and Phosphatidylserine 
exposure (38, 39). During storage mean platelet 
volume (MPV) decrease due to membrane loss from 
dendritic forms or activation or apoptosis. These lead 
to fragmentation or MP formation (40).  
PMPs can be connected to von Willebrand 
factor (vWF). VWF is a multimeric plasma 
glycoprotein that supports platelet adhesion at sites 
of vascular injury. In platelet components, it seemed 
that the binding of PMPs to vWF was affected from 
the storage media of PC (plasma and Composol). The 
binding capabilities of PMP were significantly higher 
in Composol than that of plasma at the day 4 or 7 of 
storage. However, PS exposure was not affected 
from the type of storage media (41). 
 It should be noted that MPs are found in fresh 
frozen plasma (FFP) and cryoprecipitate because 
they contain considerable number of cells (42). The 
number and type of MPs in FFP is different than 
those in peripheral blood (43) that depends on factors 
such as leukoreduction, in fact how to reduce 
leukocyte, and storage conditions .i.e. more storage 
time and freezing (44). For example, Plasma 
components prepared after an overnight hold of 
whole blood at 4 °C prior to processing contained 
increased levels of MPs Compared to plasma 
produced within 8 hours of blood donation (45). Like 
FFP, Cryoprecipitate contains significant amount of 
platelet MPs. High levels of PMPs in cryoprecipitate 
are considered to contribute to its therapeutic effects 
in bleeding patients (42). 
Do MP is an agent for blood 
transfusion reactions? 
 Whether MPs are involved in a variety of 
blood transfusion reactions is not yet proven. But 
since they considered as a storage lesion and lead to 
changes in blood components, it is not improbable 




 MPs may contribute to transfusion related 
thrombotic complications because they exhibit 
procoagulant activity by expression of PS that cause 
assembly of the coagulation factors and finally 
thrombin formation. Thrombotic effects of PMPs are 
well known (46-48) but it has also been suggested for 
RMPs.  
In a recent study, it determined that the use of 
aged RBC products (more than 28 days) lead to an 
increased incidence of deep vein thrombosis (DVT). 
But, its exact mechanism is still unclear. It is likely 
that the RMPs are involved in coagulation propagation 
and make this both through expression PS, and by 
initiating thrombin generation independently of tissue 
factor in a FXI–dependent manner (49). Moreover,  
Spinella and Colleagues reported a higher significant 
incidence (34%) of DVT in trauma patients receiving 
older blood (28 days or more) in comparison with 
blood <28 days old (16%)(50). 
TRALI 
 Transfusion related acute lung injury (TRALI) 
is one of the most serious of transfusion reactions. 
Although the TRALI mechanism is still not fully 
understood, the findings suggest that neutrophils play 
an important role in its pathogenesis (51). However, it 
is concluded that TRALI is the result of two events 
which is supported by experimental and clinical 
studies (52). The first event is the patient’s clinical 
condition and second event can be linked to an anti-
leukocytic antibody (53, 54) or antibody–independent 
such as bioactive lipids, cytokines and MPs (55). It 
can say that MPs involved in the development TRALI 
because PMPs (56, 57) and RMPs (58) can activate 
neutrophils. Furthermore, it has been reported that 
CD40 Ligand (CD40L, a member of the tumor 
necrosis factor) is a primarily platelet-derived pro-
inflammatory mediator found in soluble (sCD40L) and 
cell associated forms in transfused blood (59, 60) 
presents in platelet concentrates is a potential cause for 
TRALI (61) because studies have showed that the 
most of CD40L presents in blood is MP-associated 
(62).  
 In a study, Xie RF and Colleagues showed that 
PMPs, which carried the sCD40L, primed the formyl-
Met-Leu-Phe (fMLP)-activated PMN respiratory 
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burst. In this study, they obtained the PMP from the 
20000 g fraction by centrifugation of the stored 
platelet-free plasma. PMP was accumulated in the 
stored apheresis platelet concentrates as a vector of 
sCD40L that might interact with neutrophils and play 
an important role in developing TRALI (63).  
In another study, it was shown that among 
antibody–independent factors (cytokines, PMPs, 
RMPs, LMPs), only RMPs released from RBC 
products are suggested as potential mediators of 
TRALI, although, this needs to be investigated 
further (64).  
Effects MPs in adaptive 
immunity 
 In the immune system, direct membrane 
contact is indeed the leading way for two cells to 
communicate. Nevertheless, soluble mediators are 
also an essential link for this communication such as 
cytokines, chemokines, and hormones and so on. It 
was found that MPs derived from polymorphonuclear 
leukocytes, erythrocytes, platelets, and tumor cells 
have many effects on the innate immune system and 
on the induction of the adaptive immunity (65, 66). 
Although exact function of MPs in adaptive 
immunity is still unknown, they play a role in 
pathological conditions. For example, budding 
phenomenon from cell membrane is triggered or 
enhanced under specific physiological conditions 
such as injury, inflammation, or cancer (67). They 
also affect the immune system by changing the 
behavior of cells (68). For instance, it has 
demonstrated that following TLR activation platelets 
produce IL1β that is released through PMP production. 
Also, Platelets contribute to the inflammatory response 
to LPS through production of MPs that promote 
endothelial cell activation (69).  
In 2007, Cognasse and colleagues showed that 
Platelets have an immuno regulatory role because they 
express CD40L (CD154), which is a central marker to 
B cells and adaptive immunity function. Indeed, they 
determined that platelets can activate peripheral blood 
B cells and increase production of antibodies. In this 
study, co-culturing of platelets with B cells lead to 
mutual activation of each (70).  
 However, there was the question of how 
platelets in the body can affect the immune system 
whereas mobility of them is limited to circulation. In 
2008, Sprague and colleagues were probably given 
that platelets modulate inflammation and adaptive 
immunity at least in part by release membrane 
vesicles. In this study, it is shown that activated 
platelets release factors into the supernatant, resulting 
in production of IgG. Actually, platelet-derived 
membrane vesicles (PDMV) can be responsible 
immunity interactions so that they are sufficient to 
induce IgG production, enhance GC formation in vivo 
(71). 
 In a study, it was found that PMPs can cause 
activation B cells. PMPs were isolated from platelet 
concentrates obtained from the Tehran Blood 
Transfusion Center. In here, it was found that PMPs 
could affect B cell activation during in vitro co-
culture. As with platelets, in a comparison between 
test (B cells/PMPs) and control (B cells) cells, it was 
observed that the expression of activation markers 
Table 1. Differentiation of MPs from Exosomes and Apoptotic bodies 
Feature                      MPs                                          Exosomes                       Apoptotic bodies 
Size                           0.1-1 µm                                 0.03-0.01 µm                   1-5 µm 
Overlap in size        bacteria                                   viruses                               platelets 
Shape                       Various shapes                        Cup-shaped                      Heterogeneous    
Origin                      Plasma membrane                 Plasma membrane           Cellular 
                                  by 
#
ectocytosis                        by exocytosis 
Structure                 Phospholipid bilayer              Phospholipid bilayer       Cellular fragments 
Sedimentation       18000-20000 g                       100000-200000 g             16000 g 
Release                    Cellular activation and          Constitutive and/or         Terminal apoptosis 
                                 *early apoptosis                      Cellular activation 
# budding from the cell plasma membrane surface 
* Of note, apoptosis itself involves vesicle release  
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CD27 and CD86 increased during the seven-day co-
culture period whereas the expression of IgD 
antibody decreased (72).  
 In a recent study, it was determined that 
PMPs stimulate the production of antibodies by B-
lymphocytes. During 5-day coculture significant 
increase was observed in the production of IgG 
antibodies in the test samples (B cells+MPs) 
compared to the control (B cells in the absence of 
PMPs). In fact, PMPs can induce IgG production 
from B cells during in vitro co-culture (73).  
However, it should be noted that exosomes are 
involved in the immune system. For instance, data 
has indicated the exosomes of mast cell have 
mitogenic activity on B and T lymphocytes both in 
vitro and in vivo (74).  
Conclusion 
MPs are cell membrane derived vesicles 
which express markers of their parent cells. Briefly, 
it can be said that MPs induce balance between 
health and disease, although, exact function of MPs 
is unknown. Studies were shown that they have roles 
in the modulation of innate and adaptive immunity, 
especially of PMPs which express CD40L marker. 
Since MPs are found in blood products, they can also 
cause transfusion reactions including of TRALI and 
Thrombotic complications. Nevertheless, details 
associated with their duties in adaptive immunity 
system is unclear. Furthermore; numerous questions 
remain unanswered, for example: 
1-What is the precise function of these two sub-
groups of vesicles (i.e. MPs and exosomes)? 
2-Do solid tissues also produce vesicles? If they 
produce, what are their functions? 
3-Are all types of MPs and exosomes play a role in 
adaptive immunity system? 
4-In absence of these vesicles especially MPs, how is 
the function of the adaptive immune system? 
 However, according to the MPs demonstrated 
effects on the immune system and various diseases, 
they should be considered more important. A few 
studies have been done on the impact PMPs on the 
acquired immunity and still more studies need to be 
done in vitro and in vivo, especially in the clinical 
trial. 
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